Search results
Results from the WOW.Com Content Network
There can be multiple indications to use a procedure or medication. [2] An indication can commonly be confused with the term diagnosis. A diagnosis is the assessment that a particular medical condition is present while an indication is a reason for use. [3] The opposite of an indication is a contraindication, [4] a reason to withhold a certain ...
Indications and Usage - uses (indications) for which the drug has been FDA-approved (e.g. migraines, seizures, high blood pressure). Physicians legally can and often do prescribe medicines for purposes not listed in this section (so-called " off-label uses ").
Studies have suggested the use of naltrexone in drug courts or healthcare rehabs is a form of "post-social control," [152] or "post-disciplinary control," [153] whereby control strategies for managing offenders and addicts shift from imprisonment and supervision toward more direct control over biological processes.
[1] [2] Levacetylleucine was approved for medical use in the United States in September 2024. [1] [2] [3] Levacetylleucine is the second medication approved by the US Food and Drug Administration (FDA) for the treatment of Niemann-Pick disease type C. [2] The FDA considers it to be a first-in-class medication. [4]
In the United States, the FDA approves drugs. Before a drug can be prescribed, it must undergo the FDA's approval process. Before a drug can be prescribed, it must undergo the FDA's approval process. While a drug can feasibly be used off-label (for non-approved indications), it still is required to be approved for a specific disease or medical ...
Lumateperone was approved for medical use in the United States in December 2019 with an initial indication for schizophrenia, [4] [5] and became available in February 2020. [2] It has since demonstrated efficacy in bipolar depression and received FDA approval in December 2021 for depressive episodes associated with both bipolar I and II disorders.
The FDA label contains warnings that rasagiline may cause severe hypertension or hypotension, may make people sleepy, may make motor control worse in some people, may cause hallucinations and psychotic-like behavior, may cause impulse control disorders, may increase the risk of melanoma, and upon withdrawal, may cause high fever or confusion.
The FDA approved only the five-mg, twice-daily dose on the grounds that a higher dose was not considered to have an adequate risk-to-benefit ratio. [ 32 ] In September 2020, the FDA approved tofacitinib for the treatment of children and adolescents two years of age and older with active polyarticular course juvenile idiopathic arthritis.